Less-Frequent GLP-1 Injections May Maintain Weight Loss in Some Patients: Study
Doctor’s Role Uncovered in Smuggling Operation
USA: A small study published in Obesity found that some patients using GLP-1 weight-loss medications were able to sustain their weight reduction and related health benefits even after extending the interval between injections. The review, which examined medical records of 34 patients, indicated that administering these medications less frequently might still be effective for certain individuals.
Glucagon-like peptide-1 (GLP-1) receptor agonists have become widely used for the management of obesity due to their ability to promote substantial weight loss and improve metabolic health. However, these medications are typically prescribed as weekly injections, and stopping them abruptly often leads to weight regain and reversal of metabolic improvements. In this context, researchers explored whether a gradual reduction in dosing frequency could help maintain the benefits achieved during standard therapy.
In a retrospective case series led by Michelle Wong from the Department of Internal Medicine at Scripps Clinic in San Diego, California, investigators analyzed outcomes among adults who had already experienced successful weight reduction while receiving weekly GLP-1 receptor agonist treatment. The study focused on 30 adults who had reached a weight-loss plateau while using medications such as Semaglutide or Tirzepatide. After reaching this stage, the patients shifted from weekly injections to a reduced-frequency schedule, typically receiving the same dose every other week.
Researchers evaluated patient data at three stages: before treatment began, after weight loss had stabilized on weekly therapy, and during the maintenance period with reduced-frequency dosing. The primary outcome was the change in body weight between the plateau phase and the maintenance phase. Additional measures included changes in body composition and conditions related to Metabolic Syndrome.
Participants remained on the reduced-frequency regimen for an average of just over 36 weeks.
The analysis revealed the following findings:
- Body weight decreased significantly during the initial weekly treatment phase and remained stable, with a slight additional reduction, after the dosing interval was extended.
- Average body weight declined from about 87.9 kg before treatment to 74.1 kg at the weight-loss plateau stage.
- Weight further decreased to approximately 72.4 kg during the reduced-frequency maintenance phase.
- Total body fat and truncal fat levels reduced during treatment.
- Skeletal muscle mass remained stable after patients transitioned to the less frequent dosing schedule.
- Improvements in metabolic health markers achieved during weekly therapy were maintained after switching to the extended dosing interval.
The findings suggest that carefully planned dose de-escalation may enable some patients to maintain the benefits of GLP-1 therapy while reducing the treatment burden. According to the researchers, this approach could potentially lower medication costs, improve adherence, and help address supply constraints for these increasingly popular drugs.
The authors noted that their results provide early evidence that structured reduction in dosing frequency may serve as a practical maintenance strategy following successful weight loss with GLP-1 medications. However, they emphasized that larger randomized clinical trials will be necessary to confirm these observations and determine which patients are most likely to benefit from such tapering protocols.
Reference:Wong, M., Wu, A., Garhe, P. K., & Biermann, M. Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series. Obesity. https://doi.org/10.1002/oby.70137
Next Story